Kalytera Terminates Pre-Clinical Programs in Bone Disease – Press …

SAN FRANCISCO TEL AVIV, ISRAEL–(Business Wire)–Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the “Company
or “Kalytera“) today announced the termination of its
pre-clinical development programs in the treatment of bone disease. The
Company has determined that additional investments of time and resources
in these programs are not appropriate given the other opportunities in
its product development pipeline.

The terminated programs were evaluating three synthetic endocannabinoid
compounds, KAL436, KAL439 and KAL671, in bone fracture healing, and
osteogenesis imperfecta and osteoporosis. In connection with the
termination of these programs, Kalytera has terminated its License... read more at: http://www.digitaljournal.com/pr/3732744